Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.

Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.
复制标题

DOI:
10.1021/jm101144f
复制
发表时间:
2010-10-14
影响因子:
7.3
通讯作者:
Gray NS
Gray NS
中科院分区:
医学1区
文献类型:
--
作者:
Liu Q;Chang JW;Wang J;Kang SA;Thoreen CC;Markhard A;Hur W;Zhang J;Sim T;Sabatini DM;Gray NS

文献摘要

参考文献

被引文献

相似文献

mTOR蛋白是细胞生长和增殖的主要调节剂,其激酶活性的抑制剂有可能成为新一类抗癌药物。从在生化mTOR试验中鉴定的喹啉1开始,我们开发了三环苯并萘啶酮抑制剂Torin 1(26),其分别在2 nM和10 nM浓度下抑制细胞中mTORC 1和mTORC 2底物的磷酸化。此外,Torin 1对mTOR的选择性是PI 3 K的1000倍(EC 50 = 1800 nM),对其他450种蛋白激酶的结合选择性是100倍。Torin 1在U87 MG异种移植模型中以20 mg/kg的剂量有效,并表现出对肿瘤和外周组织中mTOR下游效应物的良好药效学抑制。这些结果表明,Torin 1是一个有用的探针的mTOR依赖性的现象,苯并萘啶酮代表了一个有前途的支架mTOR特异性抑制剂的进一步发展,具有潜在的临床效用。
The mTOR protein is a master regulator of cell growth and proliferation, and inhibitors of its kinase activity have the potential to become new class of anti-cancer drugs. Starting from quinoline 1, which was identified in a biochemical mTOR assay, we developed a tricyclic benzonaphthyridinone inhibitor Torin1(26), which inhibited phosphorylation of mTORC1 and mTORC2 substrates in cells at concentrations of 2 nM and 10 nM, respectively. Moreover, Torin1 exhibits 1000-fold selectivity for mTOR over PI3K (EC50 = 1800 nM) and exhibits 100-fold binding selectivity relative to 450 other protein kinases. Torin1 was efficacious at a dose of 20 mg/kg in a U87MG xenograft model, and demonstrated good pharmacodynamic inhibition of downstream effectors of mTOR in tumor and peripheral tissues. These results demonstrate that Torin1 is a useful probe of mTOR-dependent phenomena and that benzonaphthridinones represent a promising scaffold for the further development of mTOR-specific inhibitors with the potential for clinical utility.
DOI: 10.1016/j.cell.2006.03.035
发表时间: 2006-05-19
期刊: CELL
影响因子: 64.5
作者:
Knight, Zachary A.;Gonzalez, Beatriz;Shokat, Kevan M.
通讯作者: Shokat, Kevan M.
DOI: 10.1073/pnas.95.25.14950
发表时间: 1998-12-08
影响因子: 11.1
作者:
Aoki, M;Batista, O;Vogt, PK
通讯作者: Vogt, PK
DOI: 10.1021/ja0170302
发表时间: 2002-02-27
影响因子: 15
作者:
Ding, S;Gray, NS;Schultz, PG
通讯作者: Schultz, PG
DOI: 10.1016/j.molcel.2006.03.029
发表时间: 2006-04-21
期刊: MOLECULAR CELL
影响因子: 16
作者:
Sarbassov, DD;Ali, SM;Sabatini, DM
通讯作者: Sabatini, DM
DOI: 10.4161/cc.8.23.10070
发表时间: 2009-12-01
期刊: CELL CYCLE
影响因子: 4.3
作者:
Shor, Boris;Gibbons, James J.;Yu, Ker
通讯作者: Yu, Ker